Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
John-Michael GambleEugene ChibrikovWilliam K MidodziLaurie K TwellsSumit R MajumdarPublished in: BMJ open (2018)
Our findings suggest that the two incretin-based therapies are not associated with an increased or decreased risk of depression or self-harm.